Drug intelligence / Profile preview

gatifloxacin + fluorometholone

Development stage
Unknown
Lead developer
Cipla
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

Gatifloxacin + fluorometholone is a fixed-dose combination therapy primarily used in ophthalmology to treat inflammatory ocular conditions where a bacterial infection exists or there is a high risk of infection. Gatifloxacin is a fourth-generation fluoroquinolone antibiotic that provides broad-spectrum coverage against Gram-positive and Gram-negative bacteria by inhibiting essential bacterial enzymes involved in DNA replication. Fluorometholone is a synthetic glucocorticoid (corticosteroid) that provides anti-inflammatory effects by suppressing the release of inflammatory mediators and reducing leukocyte migration. This combination is typically formulated as an ophthalmic suspension or solution for topical application to the eye.

Brand names
Gatiquin-FGatidex-FGatifl-FGatop-FGati-FGati-P FGatiford-F
Other names
fluorometholone + gatifloxacingatifloxacin and fluorometholone
02

Targets

DNA gyraseGR (Glucocorticoid receptor)ABCB1 (P-glycoprotein)MRP2 (Canalicular multispecific organic anion transporter 1)Topo IV (Bacterial Topoisomerase IV)

Beyond the preview

Go deeper on gatifloxacin + fluorometholone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gatifloxacin + fluorometholone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call